Clinical Trials Database, ClinicalTrials.gov, EU Clinical Trials, and Google. Studies were eligible if there was an epilepsy diagnosis, participants were adults (18+ years old), and vitamin D treatment and bone outcome were provided. Articles were screened independently by 2 reviewers. Methodological quality was assessed using the Cochrane Collaboration's tool and a modified Newcastle Ottawa Scale for nonrandomized studies. Results: Nine studies were found to be eligible for this review. After vitamin D treatment, there appeared to be positive changes in bone turnover markers; 3 of 8 studies found the increase in serum calcium to be significant, 6 of 8 studies found the decrease in alkaline phosphatase to be significant, and 2 of 4 studies found the decrease in parathyroid hormone to be significant. All 6 studies that investigated bone mineralization had significant findings; however, due to varying methodologies, the impact of vitamin D on bone mineralization was inconclusive. Significance: Vitamin D does appear to have some benefit to bone health in adults with epilepsy, and therefore supplementation could potentially be a requisite to using some AEDs. To clarify the role of vitamin D supplementation to manage the adverse effect of AEDs on bone health in adults with epilepsy, longterm trials that use higher doses (>1800 IU) and measure bone mineral density are necessary.
| INTRODUCTION
Antiepileptic drugs (AEDs) are commonly prescribed medications. 1 Although second and third generation AEDs are increasingly being used to treat seizures, first generation AEDs, such as phenytoin and carbamazepine, are frequently prescribed to patients with epilepsy. 2 Although these drugs may be successful in controlling seizures, they are associated with several adverse effects, one of which is decreased bone health. Individuals with epilepsy have a higher risk of fractures than those in the general population. 3 This is partly attributable to seizures causing falls and consequently fractures, but the decrease in bone mineral density (BMD) associated with AED use also plays a significant role. 4 Moreover, the association between AED use and both decreased BMD and increased fracture rates persists after controlling for age, sex, prior fractures, and comorbid conditions. 5, 6 Carbamazepine, oxcarbazepine, phenobarbital, phenytoin, primidone, and valproate have all been implicated in the observed negative effect on bone health in individuals with epilepsy. 4, 6 These medications also induce cytochrome p450 enzymes, which decrease levels of biologically active vitamin D. 7 Interestingly, valproate is an enzyme inhibitor yet also produces a negative outcome in bone health. 4, 7 Suggested mechanisms for valproate's effect on bone density include elevating calcium levels through increased bone turnover and fewer metabolites of vitamin D or through decreased levels of proteins necessary for bone formation. 7 Vitamin D goes through several conversions in the skin and liver; a fraction of the 25-OHD from the liver is then transformed into the active form, 1,25(OH)2D, mainly in the kidneys. 8 Vitamin D is metabolized through 3 primary steps:
25-hydroxylation, 1a-hydroxylation, and 24-hydroxylation. These conversions occur via cytochrome p450 enzymes, as does the metabolism of 1,25(OH)2D to less active forms. 9 These include CYP2R1, CYP27A1, CYP27B1, CYP24A1, and CYP3A4. 9 Given multiple cytochrome p450 enzymes in multiple locations, the metabolism of vitamin D is complex. The more stable 25-OHD form is used as a measure of the body's vitamin D supply 8 ; 1,25(OH)2D upregulates its own degradation and is short-lived. 9 Deficiency as defined by serum 25-OHD results in decreases of both 1,25(OH)2D and calcium, 8 both essential components of bone formation.
Induction of p450 enzymes by AEDs, particularly CYP24 and CYP3A4, 4, 9 may decrease the active 1,25(OH)2D by enhancing both its degradation and the conversion of 25-OHD to inactive metabolites. The importance of vitamin D in bone formation and maintenance is well established. Its role in the prevailing theory linking AEDs to decreased BMD further supports its use to mitigate adverse effects in people taking AEDs.
Several studies have explored the use of vitamin D as a bone health intervention. The purpose of this systematic review was to investigate the effect of vitamin D supplementation on bone health in adults with epilepsy who take AEDs. To our knowledge, this is the first review to systematically investigate the effect of vitamin D on bone health in people taking AEDs for epilepsy.
(eg, multiple bone turnover markers or bone mineralization) demonstrated to be attributable to the intervention. Studies with children were excluded due to rapid changes in bone associated with growth. Only completed studies with original data were eligible; publications summarizing previously published studies were excluded, and for eligible studies with overlapping patients, the study with a larger sample size was kept.
Studies were excluded if they evaluated serum vitamin D levels and/or serum calcium levels only. Reviews, letters, and case studies were excluded. Non-English studies were excluded.
All studies were screened by 2 members of the research team (H.F. plus either C.D.H. or M.F.; see Acknowledgments). Discrepancies were discussed by all 3 reviewers until agreement was reached.
| Data extraction
The following data were extracted from eligible studies: authors, publication year, study location, study methodology, sample details, intervention details, and outcome measurements.
| Quality assessment
The methodological quality of included studies was independently assessed by 2 reviewers (H.F. and H.T.M.) using a modification of the Newcastle-Ottawa Scale for nonrandomized studies 12 and the Cochrane Collaboration tool for risk of bias assessment for randomized studies. 13 3 | RESULTS
| Search results
Searches returned 769 articles, 611 after removing duplicates. Fifty-six articles were retrieved for full-text review based on title and abstract (kappa coefficient = 0.905, 95% confidence interval = 0.843-0.966); 9 met all eligibility criteria (kappa coefficient = 0.827, 95% confidence interval = 0.639-1.000). See Figure 1 for the PRISMA flow diagram detailing the inclusion and exclusion of articles.
| Studies selected
Four randomized clinical trials (RCTs) and 5 nonrandomized, quasiexperimental studies (QEs) were eligible for this review. [14] [15] [16] [17] [18] [19] [20] [21] [22] Ages of participants ranged from 18 to 92 years. All studies included both males and females; the proportion of female patients ranged from 17% to 73%. Sample size ranged from 6 to 226. Study length ranged from 1 to 12 months. Patients in the studies used various AEDs: phenobarbital, phenytoin, primidone, carbamazepine, valproate, topiramate, lamotrigine, gabapentin, and clonazepam (Table 1) . Only 1 of the 9 studies investigated patients taking non-enzyme-inducing AEDs. 15 One of the 9 studies restricted its participants to those who had evidence of osteopenia and at least 1 documentation of hypocalcemia, 21 and 2 recruited patients with an increased amount of osteoid or an increase in osteocytic osteolysis. 16, 18 The control group in 1 of the 9 studies consisted of patients treated for intellectual disabilities; they shared the same lifestyles as the epileptic patient group but were not taking AEDs. 17 (Table 1) . Of the 7 studies that measured alkaline phosphatase, 1 stated that the bone-specific isoenzyme was measured, 22 whereas 6 measured total serum alkaline phosphatase. Descriptions of outcomes measured are provided in Appendix S1.
| Quality assessment
The methodological quality of included studies indicated all were of at least adequate quality (each scoring 50% or higher on the scales used), with RCTs consistently scoring higher (see Appendices S2 and S3). The mean rating for RCTs was 4.5 of a possible total of 6 using the Cochrane Collaboration tool, 13 whereas QEs had a mean rating of 15.4 of a possible 21 in the modified Newcastle-Ottawa Scale. 12 
| Baseline (preintervention) findings
Before examining changes after vitamin D administration, some studies compared the initial state of bone health indicators in people with epilepsy with that of controls.
| Serum measurements
Differences in baseline serum 25-OHD, calcium, ALP, PTH, and inorganic phosphate/phosphorous were found between patients with epilepsy and controls (see Table 2 ). Offermann and colleagues noted that 90.5% of patients with epilepsy had serum 25-OHD levels < 15 ng/mL, as opposed to 69.2% of controls (Table 2) . 17 Without comparing to controls, Mikati and colleagues found that 34% of their patients with epilepsy had serum 25-OHD levels < 10 ng/mL and 46% were between 10 and 20 ng/mL, 15 and Pedrera and colleagues found that 36% of their patients with epilepsy had serum 25-OHD levels < 15 ng/mL.
14 In Offermann's study, it was noted that 71.6% of their epilepsy patients had subnormal serum calcium levels (<2.25 mmol L À1 or 9.00 mg/dL) as compared with 50.0% of controls 17 ; in Sherk and Snape's study, groups with epilepsy had mean serum calcium levels ≤ 9.00 mg/dL, whereas the control groups had higher means (9.6 and 9.9 mg/dL for males and females, respectively). 20 All other studies, whether differences between controls and patients were significant or not, had mean serum calcium levels > 9.00 mg/dL. Offermann and colleagues noted that 83.2% of patients with epilepsy had serum PTH levels > 110 pg/mL as compared to 79.2% of controls, 17 and Pedrera and colleagues found that 17% of the patients had serum PTH levels that were above upper accepted limits. 
| Bone mineralization
Of 6 studies that investigated bone mineralization, the 5 that investigated baseline values found bone mineralization was lower in those with epilepsy compared to controls. [14] [15] [16] 19, 21 One study completed quantitative morphometric analyses of biopsies, providing a more in-depth picture of bone health (see Table 3 ).
Christiansen and colleagues found that the initial bone mineral content (BMC) of patients with epilepsy (87% AE 16% of the calculated normal value) was significantly lower (P < .001) than in those without epilepsy. 19 Hahn and Halstead found that in patients with epilepsy, forearm bone mass was significantly lower (P < .02) than in controls: 81.7% AE 4.7% of age-sex norm in epilepsy patients versus 101.4% AE 2.1% in controls. 21 Mikati and colleagues found that BMD was significantly lower (P < .05) at all sites in patients with epilepsy compared to both their own age-, sex-, and ethnicitymatched nonepileptic controls and the manufacturer's database age-matched control values. 15 T scores for lumbar spine (À0.87 AE 1.06), total hip (À0.58 AE 0.93), femoral neck (À0.70 AE 0.97), trochanter (À0.5 AE 0.94), and onethird radius (À0.85 AE 1.05) were compared to zero; a score below zero denoted a mean BMD less than the mean from the manufacturer's database. 15 Pedrera and colleagues found that amplitude-dependent speed of sound measurements of nondominant hands were significantly lower (P < .0001) in patients with epilepsy (1926 AE 104 m/s) than in controls (2036 AE 74 m/s). Five of 6 studies that measured changes in serum 25-OHD levels noted a significant increase 14, 18, 21, 22 ; 3 of 8 studies found a significant increase in calcium [20] [21] [22] ; 6 of 8 studies studies found a significant change in serum inorganic phosphate/phosphorous, either an increase 21 or a decrease 16 (see Table 2 ). Offermann and colleagues noted a seasonal change in serum 25-OHD and calcium that appeared to be dose-dependent in individuals taking vitamin D supplements, such that higher dosed groups experienced larger, although not significant, increases. 17 They also noted that vitamin D administration lowered the frequency of abnormal PTH levels in their patients. 17 
All 6 studies that investigated bone mineralization observed some positive changes after vitamin D treatment, [14] [15] [16] 18, 19, 21 although of these 1 study found a change in bone morphology but not BMD. 18 Two studies found several significant differences in bone morphology after vitamin D treatment using biopsies (see Table 3 ). 16, 18 Mosekilde and colleagues noted that posttreatment both mean volume of periosteocytic lacunes and percentage of trabecular bone surface active in bone mineralization in patients were no longer significantly higher than in controls but that even after significant decreases posttreatment the percentage of osteoid surfaces and resorption surfaces remained significantly elevated compared to controls (P < .01 and P < .05, respectively). 16 Hoikka and colleagues noted that 5 of the sample of 9 patients' osteoid volumes returned to a normal range posttreatment. 18 When comparing patients with epilepsy to those without on the same regimen, BMC increased significantly (P < .001) by 4.9% above baseline values, whereas there was no significant change in controls. 19 A significant increase of 4.6% (P < .02) in forearm bone mass from baseline was observed in patients after vitamin D treatment. 21 Mikati and colleagues found that BMD of patients in their low-dose arm of 400 IU daily for 12 months did not change significantly from baseline; however, patients in the high-dose arm of 800 IU had a significant increase at several sites: lumbar spine (P < .03), total hip (P < .02), and one-third radius (3 of 5 sites, P < .04). 15 This increase was <1% from baseline. Patients in the low-dose arm were significantly older than those in the high-dose arm (P < .01), and their duration of AED therapy was significantly longer (P < .04). 15 According to linear regression conducted by the researchers, age and AED duration did not appear to influence the results in the 2 treatment arms. 15 Hoikka and colleagues found no statistically significant difference in BMD from baseline in patients with epilepsy after vitamin D treatment. 18 Pedrera and colleagues found that ultrasound measurements of nondominant hands increased significantly (P < Table 4 ). The addition of vitamin D appeared to influence impact on bone health indicators; in 1 study calcium alone significantly decreased serum calcium levels and increased already elevated ALP in patients, whereas combination treatment significantly increased serum calcium and decreased serum ALP 22 ; in the second study, significantly higher BMC was only observed with the addition of vitamin D. 19 
| DISCUSSION
Our systematic review is the first to investigate the effect of vitamin D supplementation on bone health in adults with epilepsy who take AEDs. Bone health is compromised in people with epilepsy. Decreased BMD and increased risk of fractures, particularly in those taking enzyme-inducing AEDs that decrease biologically active vitamin D levels, have been demonstrated. 4, 6 This review addresses the impact of supplemental vitamin D given to patients to manage this adverse effect. Typically, all outcomes assessed in this review showed some improvement after vitamin D supplementation. At baseline, considerable proportion of adults with epilepsy were either vitamin D deficient or insufficient. Vitamin D deficiency has been classified as a 25-OHD level of <10 ng/mL 8 and insufficiency as <20 ng/mL. 23 More recent research has classified vitamin D deficiency as a 25-OHD level of <20 ng/mL and insufficiency as <30 ng/ mL. 8 In the studies reviewed, patients with epilepsy had lower serum levels of vitamin D and calcium, up to 14, 18, 19, 22 or, mean AE standard error. 16, 21 The study by Mikati et al. 15 did not present consistent values for 25-OHD at baseline; this study is not listed in this competitive-binding assays, which may yield higher measurements than the high-performance liquid chromatography method used by the other 2 studies. 18, 22 Vitamin D treatment increased serum 25-OHD and calcium levels. This has also been found in other studies investigating vitamin D treatment to correct 25-OHD levels in patients with epilepsy. 26, 27 Although within-study preand posttreatment differences are valuable, the reliability of interstudy comparisons is equivocal. This reinforces the necessity of examining other bone health indicators when determining both osteoporosis risk and efficacy of supplementation if the goal is to find a measurable range to use in clinical practice for people taking AEDs. Two of 4 studies in this review that investigated inorganic phosphate/phosphorous found significant differences, either higher or lower, between patients and controls pretreatment, which were normalized by a statistically significant amount after vitamin D treatment. 16, 21 In the reviewed studies, people with epilepsy typically had elevated levels of ALP and PTH, which decreased after vitamin D treatment. Several case reports of people with epilepsy on long-term AED therapy have noted elevated ALP levels. 28 ALP and PTH are bone turnover markers; elevated levels can indicate abnormal bone formation. 29 However, abnormal PTH levels may occur for a number of reasons, decreasing its usefulness in determining bone health. Evidence shows that elevated ALP levels has been significantly associated with osteoporotic fractures, 30 and a systematic review of 134 reports found moderate correlations between high ALP levels and low BMD scores; elevated ALP levels among patients being treated with AEDs T A B L E 3 Biopsy results in controls and patients with epilepsy 16, 18 might indicate a need for osteoporosis screening. 31 It may also be possible to determine the range at which ALP levels are a concern and treatment should be initiated. To our knowledge, this avenue has not been explored, and further investigation is recommended. It is important to note that ALP has a number of sources, including bone and liver. AEDs are hepatic enzyme inducers, and elevated ALP may indicate liver health rather than bone health. However, hepatotoxicity is a rare side effect of AEDs and is often idiosyncratic and not dose-dependent; therefore, raised total serum ALP levels may not necessarily be indicative. 32 One study in this review measured bone-specific ALP and observed a reduction after vitamin D treatment similar to other studies that measured total ALP. 22 Two studies measured other markers of liver health and concluded that their findings of decreased ALP were attributable to bone health, 14, 17 and Hahn and Halstead cited findings from their previous study to indicate a bonerelated source for the observed reduction in ALP. 21 ALP changes observed in these studies were noted after vitamin D intervention, while AED use remained constant; likely these were of bone rather than liver origin. Regardless, bone-specific ALP would be more compelling evidence in clinical practice. The effect of vitamin D treatment on bone mineralization was a challenge to ascertain because of different measures used (ie, BMD, BMC, hand ultrasounds, and biopsies). All 6 studies that investigated bone mineralization found some positive change in at least 1 measure used. [14] [15] [16] 18, 19, 21 The duration of supplementation, ranging from 1 to 12 months, may be a confounding factor. A 6-month intervention with vitamin D supplementation did not see any change in BMD, 18 whereas a 12-month intervention did. 15 That 6-month intervention did find significant improvements in bone morphology, which may suggest that some bone mineralization measurements need a longer treatment period to yield observable results. 18 Another potential confounder is dosing, which ranged from 214 to 120 000 IU.
14,17 A study administering either 400 or 4000 IU daily noted no changes in BMD in their low-dose treatment arm, 15 which is consistent with research that has found doses < 800 IU to be of little effect.
33-35
The high-dose arm was within a range suggested to be effective 15 and resulted in a significant BMD increase of <1%.
15 This is comparable to a clinical trial that investigated 1000-1500 mg calcium and 500-750 IU vitamin D daily paired with placebo or 35 mg risedronate weekly in 27 male veterans with epilepsy, which found a small but significant decrease of <2% from baseline in total body BMD in the placebo arm after 2 years compared to a nonsignificant increase of <0.085% in the risedronate arm. 36 The difference in efficacy between supplementation alone and with pharmacotherapy was not significant. 36 Participants with subnormal serum calcium and vitamin D were excluded from the trial, which may have had implications for the usefulness of supplementation. 36 Similarly, it is important to note that Mikati's study is the only one in our review that included patients who were taking nonenzyme-inducing AEDs. 15 This may have influenced the results, as the effect of vitamin D may be different for non-enzyme-inducing AEDs as compared to enzymeinducing AEDs. Although all patients with epilepsy in the reviewed studies were 18 years or older, participants' age, the AED (s) taken, and the treatment history varied considerably. Differences in diet and exercise in patients also serve as possible confounders. Offermann et al did not use healthy controls, limiting the interpretation of their results and the usefulness of their between-group comparisons. 17 Hahn and
Halstead restricted their participants, which may have played a role in the significant increase in forearm bone mass observed posttreatment, a bone health indicator not measured in the other reviewed studies. 21 Both studies that used biopsies restricted their patient groups, which may limit the reproducibility of their results in all patients with epilepsy. 16, 18 Moreover, the heterogeneity of study methodologies makes findings difficult to generalize. Different types of vitamin D supplementation (eg, D2, D3, 25-OHD) introduced another possible confounder. We found no relationship between type of vitamin D administered and efficacy, nor can we draw conclusions on optimal length of treatment. Christiansen et al's follow-up to their 1973 investigation used a similar protocol but compared calcium paired with either 25-OHD or vitamin D3, rather than the original vitamin D2 and without a calcium-only control arm; they did not find significant improvements in BMC, unlike their first study, which they attributed to the type of vitamin D used. 37 Two subsequent randomized, doubleblinded trials testing calcium paired with 4000 IU/d of vitamin D2 or D3 for 6 months found no difference in patients using carbamazepine 38 but found that vitamin D2 was effective in patients using phenobarbitone and primidone. 39 Whether this means that only some types of vitamin D are effective in improving bone health in people taking AEDs or whether this has implications for which specific AEDs are responsive to vitamin D treatment is not known. Further studies are warranted. Taking calcium, vitamin D, or both is frequently recommended to maintain bone health. Two systematic reviews on calcium and vitamin D for fracture outcomes found calcium to be of benefit and noted that doses of vitamin D > 800 IU are necessary for observable outcomes; the Cochrane review that found less favorable evidence for vitamin D treatment did not include any trials with doses > 800 IU. 33, 34 Low doses of vitamin D did not show benefit in these reviews, and calcium appears to be the more FERNANDEZ ET AL.
| 893 effective supplement to maintain bone health in the general population. However, for people with epilepsy, vitamin D plays a significant role in the mechanism that links many AEDs to bone health. Seven of the 9 studies in our review assessed vitamin D treatment and found that at least 1 indicator of bone health appeared to improve. [14] [15] [16] [17] [18] 20, 21 The remaining 2 studies evaluated the efficacy of combined vitamin D and calcium supplementation relative to that of calcium alone, and the inclusion of vitamin D appeared to provide significant benefit. 19, 22 It is worth noting that 1 of these studies used a low dose of 400 IU vitamin D yet still found significant results. 22 It is possible that the addition of calcium may have played a role in this. The dose of vitamin D, with or without calcium, necessary to see improvements in bone health is not yet known, although doses of 800 IU have been suggested when used in combination with calcium 33 and 1800-4000 IU when used alone. 35 Only 9 studies met our eligibility criteria; they were methodologically heterogeneous and conducted over a span of 4 decades. The methodological quality of the reviewed studies ranged from medium to low risk of bias. The major concern between studies was a lack of replication. The effect of vitamin D treatment on bone mineralization suffers the most from a lack of standardized protocol and is, arguably, the most important outcome of bone health, as it is a more direct measure than bone turnover markers such as ALP and PTH and more reliable than 25-OHD assays. Findings linking vitamin D with bone health improvement are not fully conclusive. Many concerns have not been addressed, including type of vitamin D dose and duration of intake. There is also a lack of research that investigates fracture outcomes, which may be of more clinical significance. Long-term intervention studies with healthy controls that include comparable dosing schedules of vitamin D (preferably 1800-4000 IU daily 35 ), bone turnover markers, BMD measurement, and fracture outcomes are required to clarify the clinical role vitamin D supplements play in bone health management in patients taking AEDs.
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